TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05840731

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo means that the capsules will not contain Ashwagandha but some other inactive substance.
Study: NCT06712316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion
Study: NCT05257577

Intervention type: PROCEDURE
Intervention: Breast conserving surgery
Description: Patients receive standard of care breast surgery and subsequent whole breast irradiation
Study: NCT06112340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linsitinib
Description: Study medication taken twice daily by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linsitinib
Description: Study medication taken twice daily by mouth
Study: NCT06114628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (B)
Description: Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (B)
Description: Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (B)
Description: Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (B)
Description: Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (B)
Description: Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (B)
Description: Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.
Study: NCT06712316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Intravenous infusion
Study: NCT05317195

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP-4
Description: NP-4; 3.6 mg nicotine; pH 8.0; moisture 30

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Velo-NP
Description: Velo-NP; 10 mg nicotine;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Velo-NP
Description: Velo-NP; 10 mg nicotine;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Velo-NP
Description: Velo-NP; 10 mg nicotine;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Velo-NP
Description: Velo-NP; 10 mg nicotine;

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Velo-NP
Description: Velo-NP; 10 mg nicotine;

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Velo-NP
Description: Velo-NP; 10 mg nicotine;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zyn-NP
Description: Zyn-NP; 3 mg nicotine;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zyn-NP
Description: Zyn-NP; 3 mg nicotine;
Study: NCT06114628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid (D)
Description: Oral daily dosage of 300mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid (D)
Description: Oral daily dosage of 300mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid (D)
Description: Oral daily dosage of 300mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid (D)
Description: Oral daily dosage of 300mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid (D)
Description: Oral daily dosage of 300mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid (D)
Description: Oral daily dosage of 300mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid (D)
Description: Oral daily dosage of 300mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid (D)
Description: Oral daily dosage of 300mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid (Pa)
Description: Oral daily dosage of 200mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid (Pa)
Description: Oral daily dosage of 200mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (M)
Description: Oral daily dosage of 400mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (M)
Description: Oral daily dosage of 400mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (M)
Description: Oral daily dosage of 400mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (M)
Description: Oral daily dosage of 400mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (M)
Description: Oral daily dosage of 400mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (M)
Description: Oral daily dosage of 400mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid (L)
Description: Oral daily dosage of 600mg for the first 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid (L)
Description: Oral daily dosage of 600mg for the first 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide (Z)
Description: Oral daily dosage of 1200mg-2000mg depending on weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (Z)
Description: Oral daily dosage of 1200mg-2000mg depending on weight.
Study: NCT05317195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zyn-NP
Description: Zyn-NP; 3 mg nicotine;
Study: NCT06114628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (Z)
Description: Oral daily dosage of 1200mg-2000mg depending on weight.
Study: NCT05317195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zyn-NP
Description: Zyn-NP; 3 mg nicotine;

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zyn-NP
Description: Zyn-NP; 3 mg nicotine;

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zyn-NP
Description: Zyn-NP; 3 mg nicotine;
Study: NCT06635876

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaching Sessions
Description: The coach will use motivational interviewing techniques to:~1. To assist and guide the caregiver to establish a standby caregiver relationship~2. To assist and guide the caregiver as to how to use the EPT
Study: NCT05940233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: In the experimental group, we give the Letrozole 10 mg PO daily on the 4th day before Misoprostol 800 mcg SL on the 4th day. In the control group, we give Misoprostol 800 mcg SL on the 4th day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: In the experimental group, we give the Letrozole 10 mg PO daily on the 4th day before Misoprostol 800 mcg SL on the 4th day. In the control group, we give Misoprostol 800 mcg SL on the 4th day.
Study: NCT06114628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (Z)
Description: Oral daily dosage of 1200mg-2000mg depending on weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin (R)
Description: Oral daily dosage of 450mg-750mg depending on weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid (H)
Description: Oral daily dosage of 225mg-375mg depending on weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol (E)
Description: Oral daily dosage of 825mg-1375mg depending on weight.
Study: NCT06712316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous infusion
Study: NCT06227351

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: completely limiting computer generated surgical three-dimensional guide
Description: Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to the zygoma anatomy-guided approach classification and previously planned surgery using Cone beam C.T lateral window and sinus foor lifting will be decided to be done or not.~After securing the surgical templates in its proper position, sequential osteotomy drilling will be performed in a steady in and out movement under copious sterile saline irrigation.The drills will be entering the maxilla palatally and puncturing the alveolar crest to reach the buccal side.The drills will be visualized through the bony window created until it reaches the zygomatic bone.Sequential drills with the uses of guided tubes,sleeves and keys will be used to guarantee that the implant have been placed in a fully completely guided manner.Afterwards the zygomatic implants will be placed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partially limiting computer generated surgical three-dimensional guide
Description: Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full -thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to zygoma anatomy-guided approach classification and previously planned surgery using cone beam C.T.lateral window and sinus floor lifting will be decided to be done or not.After securing the surgical templates,The first drill only will be used using the guide then it will be removed and the other drills will be completed in a free hand without the use of guide to guarantee that the implant will be placed in partially guided manner.Afterwards the zygomatic implants will be placed.
Study: NCT05903339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V3G CH848 Pr-NP1 60mcg
Description: (60 mcg)
Study: NCT06712316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Intravenous infusion
Study: NCT06707818

Intervention type: OTHER
Intervention: Preoperative Interventions
Description: During the initial surgical consultation, participants will provide informed consent. Demographic data and several validated assessment scales will be collected, including the Perceived Socioeconomic Status Scale (8), Ten-Item Personality Inventory (9), Pain Catastrophizing Scale (10), Hospital Anxiety and Depression Scale (11), Rosenberg Self-Esteem Scale (12), Quality of Recovery-15 (QoR-15) questionnaire (13), and the Visual Analog Scale (VAS) for pain (14).
Study: NCT05249699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: prevent the development of tuberculosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: prevent the development of tuberculosis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: without any additional anti-tuberculosis treatment
Description: reduce the number of Participants With Treatment-Related Adverse Events
Study: NCT06558136

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
Study: NCT05984381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: prednisolone 0.75mg/kg/day (a maximum dose of 40mg at baseline) orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: prednisolone 0.75mg/kg/day (a maximum dose of 40mg at baseline) orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone
Description: Dapsone 100 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 15 mg weekly
Study: NCT05759611

Intervention type: OTHER
Group type: OTHER
Intervention: Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises
Description: Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises lasting about 20 minutes per session
Study: NCT06707818

Intervention type: OTHER
Intervention: Intraoperative Interventions
Description: All surgical procedures will follow the standard general anesthesia protocol of the hospital. General anesthesia induction will involve propofol (1-2 mg/kg), fentanyl (1 mcg/kg), and rocuronium (0.6 mg/kg) for endotracheal intubation. Anesthesia maintenance will be performed with desflurane (4-6%) and remifentanil (0.1 mcg/kg/min), with adjustments as needed based on blood pressure and heart rate. Post-induction, dexamethasone (4 mg) will be administered for anti-inflammatory effects. To support postoperative pain management, tramadol (1 mg/kg), ibuprofen (400 mg), and paracetamol (1 g) will be administered before the end of the procedure. Ondansetron (4 mg) will be used for nausea prophylaxis. All intraoperative medications and dosages will be recorded without intervention.
Study: NCT05620836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral, Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral, Tablet
Study: NCT05759611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program
Description: Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + a specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects.
Study: NCT05983588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAVICTI 1.1 g/ml
Description: Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)
Study: NCT06707818

Intervention type: OTHER
Intervention: Postoperative Interventions
Description: In the recovery room, analgesic interventions will follow the hospital's standard protocol: patients with VAS scores between 3 and 7 will receive 25 mcg of fentanyl, while those with scores above 7 will receive 50 mcg.~All patients will receive standard multimodal analgesia during the ward stay, including paracetamol (1 g, three times daily) and ibuprofen (400 mg, twice daily). Patient-controlled analgesia (PCA) devices will administer tramadol (10 mg IV per patient request, without continuous infusion).
Study: NCT06709209

Intervention type: PROCEDURE
Intervention: Colonoscopy after bowel cleansing
Description: Colonoscopy will be performed using HD-WLE; TXI; RDI and NBI.

Intervention type: PROCEDURE
Intervention: Intestinal biopsies
Description: During colonoscopy, at least 2 biopsies from each segment will be taken as standard of care to assess inflammation in UC

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: Blood samples will be taken for standard of care by appropriately trained members of the clinical research team. The results of the standard of care blood will be used in the research.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool
Description: The stool sample will be sent to the laboratory for Faecal Calprotectin (FCP) as a marker of disease activity.

Intervention type: OTHER
Intervention: Clinical follow-up
Description: Patients will be followed-up at 6 and 12 months after index endoscopy. Patients will be evaluated in clinic or by telephone call and the disease will be reassessed. Partial Mayo Score (PMS) and occurrence of clinical outcomes will be evaluated.
Study: NCT06711588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: As-prescribed stiffness
Description: A novel prosthesis that includes a low-profile prosthetic foot whose stiffness category is determined by the person's body weight and activity level (standard clinical practice).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: As-prescribed stiffness
Description: A novel prosthesis that includes a low-profile prosthetic foot whose stiffness category is determined by the person's body weight and activity level (standard clinical practice).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: As-prescribed stiffness
Description: A novel prosthesis that includes a low-profile prosthetic foot whose stiffness category is determined by the person's body weight and activity level (standard clinical practice).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: As-prescribed stiffness
Description: A novel prosthesis that includes a low-profile prosthetic foot whose stiffness category is determined by the person's body weight and activity level (standard clinical practice).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: As-prescribed stiffness
Description: A novel prosthesis that includes a low-profile prosthetic foot whose stiffness category is determined by the person's body weight and activity level (standard clinical practice).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: As-prescribed stiffness
Description: A novel prosthesis that includes a low-profile prosthetic foot whose stiffness category is determined by the person's body weight and activity level (standard clinical practice).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: As-prescribed stiffness
Description: A novel prosthesis that includes a low-profile prosthetic foot whose stiffness category is determined by the person's body weight and activity level (standard clinical practice).
Study: NCT05620836

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, Tablet
Study: NCT04973111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-868 as SC Injection
Description: CT-868

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo as SC Injection
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator as SC Injection
Description: Active Comparator
Study: NCT05323786

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The combined topical anesthesia induction group
Description: Inhalation of aerosolized surface anesthesia with 10 ml 2% lidocaine would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia with 3ml 2% lidocaine.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: The routine induction group
Description: Inhalation of 10 ml 0.9% normal saline would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, 3ml 0.9% normal saline would be administered into subglottic airway with a catheter.
Study: NCT06235463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Pedal Pump
Description: Participants randomized to this condition will receive 5 minutes of myofascial release to the thoracic inlet and 5 minutes of the pedal pump technique.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light Touch Treatment
Description: Participants randomized to receive the sham treatment will receive light touch from the operator on the base of the neck and the balls of the feet. This light touch is meant to mimic the pedal pump through touching the same areas of the body but without palpating so that no lymphatic fluid is removed from the lower limbs.
Study: NCT05903339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V3G CH848 Pr-NP1 60mcg
Description: (60 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M-052-AF 5mcg
Description: (5 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M-052-AF 5mcg
Description: (5 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alum 500 mcg
Description: (500 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alum 500 mcg
Description: (500 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V3G CH848 mRNA-Tr2 50mcg
Description: (50 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V3G CH848 mRNA-Tr2 50mcg
Description: (50 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V3G CH848 mRNA-Tr2 50mcg
Description: (50 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V3G CH848 mRNA-Tr2 50mcg
Description: (50 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACU-026-001-1 2.0mg
Description: (2.0 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACU-026-001-1 2.0mg
Description: (2.0 mg)